Search

Background: Anemia is often considered to be a risk factor for cerebral venous thrombosis (CVT). We investigated the association between anemia and CVT. Methods: 42 postpartum /puerperal females were studied retrospectively for various factors like anemia, conscious level at admission, place of delivery (home or hospital) and their neurological sequel was measured at the time of discharge. Platelets counts were also noted (to rule out thrombocytosis). Anemia was defined according to World Health Organization criteria: non- pregnant women hemoglobin < 7.5 gm/dl, pregnant women < 6.9gm/dl. Modified Rankin Score (mRS) was taken as a scale for recovery. Results: Patients with CVT were younger (mean age 28). Anemia was more frequent in 32.7%. Hemoglobin as a continuous variable was inversely associated with CVT. Platelets counts, BT CT were normal hence no thrombocytosis was seen. No gross increase in WBC count was noted indicating absence of sepsis (puerperal). Outcome was favorable in 83% patients. N=4 (7%) patients died. Conclusions: We concluded that there is a positive correlation with increased levels of HbA1c and FBS (p˂0.001) in diabetic postmenopausal women and knee osteoarthritis. we found a significant association of severe anemia and CVT in patients of CVT of non-infectious origin, although the exact mechanism leading to hypercoagulability remains unclear and had poor prognosis.

Background: To assess the effect of Hypertension and Diabetes on Left Ventricular Diastolic Function. Methods: 2D Echocardiography was performed in 295 subjects. Subjects were divided into two groups – Group 1 having hypertension (HTN) and Group 2 having diabetes mellitus only (DM). Patients with cardiac illness like heart failure, myocardial infarction, arrhythmias were excluded from the study. The procedure was explained and consent was obtained from the patients. All the subjects underwent detail clinical examination. Height, weight, blood pressure, blood sugar, lipid profile, ECG was done. Early peak Diastolic (E) and late peak diastolic (A) transmitral flow were recorded. E/A was calculated. Data are presented as Mean ± Standard Deviation for continuous variables and as proportions for categorical variables. The X2 test was used to test differences between proportion. Multiple linear regressions were performed to assess the independent association of hypertension and diabetes with Diastolic function parameters. Differences between Hypertension and Diabetes group were assessed by one way analysis of variance. (Performed using STATA). Results: Correlation of hypertension and diabetes with Diastolic function parameters. Diabetes subjects had significantly higher A wave (P

Background:Diabetes mellitus is now affecting individuals of all age group and socioeconomic status. Besides other complications of the diabetes mellitus, skin is affected by the acute metabolic derangements as well as by chronic degenerative complications of diabetes. To evaluate the prevalence of skin manifestations in patients with diabetes mellitus. To analyze the prevalence and pattern of skin disorders among diabetic patients in North part of Uttar Pradesh. Methods: This Prospective study was conducted on 40 diagnosed Type 2 diabetic patients having skin lesions attending the Department of Medicine, Ananta Institute of Medical Sciences & Research Center, Rajsamand, Rajasthan were included in our study on the basis of inclusion and exclusion criteria. Out of 40 patients, only 25 patients were completed the whole study done during the duration of 3 months (March 2016 to May 2016. Results: The common skin disorders were: diabetic dermopathy (44%), Xerosis (36%), skin tags (32%), cutaneous infections (31%), and seborrheic keratosis (30%). Conclusions: Skin is involved in diabetes quite often and the manifestations are numerous. Most of the patients were affected from Diabetic dermopathy.

Context Glucose-insulin-potassium (GIK) infusion is a widely applicable, low-cost therapy that has been postulated to improve mortality in patients with acute ST-segment elevation myocardial infarction (STEMI). Given the potential global importance of GIK infusion, a large, adequately powered randomized trial is required to determine the effect of GIK on mortality in patients with STEMI. Objective To determine the effect of high-dose GIK infusion on mortality in patients with STEMI. Design, setting, and participants Randomized controlled trial conducted in 470 centers worldwide among 20,201 patients with STEMI who presented within 12 hours of symptom onset. The mean age of patients was 58.6 years, and evidence-based therapies were commonly used. Intervention Patients were randomly assigned to receive GIK intravenous infusion for 24 hours plus usual care (n = 10,091) or to receive usual care alone (controls; n = 10,110). Main outcome measures Mortality, cardiac arrest, cardiogenic shock, and reinfarction at 30 days after randomization. Results At 30 days, 976 control patients (9.7%) and 1004 GIK infusion patients (10.0%) died (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.95-1.13; P = .45). There were no significant differences in the rates of cardiac arrest (1.5% [151/10 107] in control and 1.4% [139/10,088] in GIK infusion; HR, 0.93; 95% CI, 0.74-1.17; P = .51), cardiogenic shock (6.3% [640/10 107] vs 6.6% [667/10 088]; HR, 1.05; 95% CI, 0.94-1.17; P = .38), or reinfarction (2.4% [246/10,107] vs 2.3% [236/10,088]; HR, 0.98; 95% CI, 0.82-1.17; P = .81). The rates of heart failure at 7 days after randomization were also similar between the groups (16.9% [1711/10,107] vs 17.1% [1721/10,088]; HR, 1.01; 95% CI, 0.95-1.08; P = .72). The lack of benefit of GIK infusion on mortality was consistent in prespecified subgroups, including in those with and without diabetes, in those presenting with and without heart failure, in those presenting early and later after symptom onset, and in those receiving and not receiving reperfusion therapy (thrombolysis or primary percutaneous coronary intervention). Conclusion In this large, international randomized trial, high-dose GIK infusion had a neutral effect on mortality, cardiac arrest, and cardiogenic shock in patients with acute STEMI.